Navigation Links
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Date:3/31/2008

s-Eluting Coronary Stent System. PROMUS is designed, studied and manufactured by Abbott and supplied as part of a distribution agreement between the two companies.

Everolimus is licensed to Abbott by Novartis for use on its drug eluting stents.

For images of Abbott's XIENCE V stent and other information, please visit the company's online newsroom at http://www.abbottvascular.com/presskit.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 68,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
4. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
5. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...e/ -- Radius Health ("Radius") announced today tha...econd institutional financing round, increasing to...otal amount raised since the company,s inception t...tors participated in the financing, led by MPM Bio...The Wellcome Trust, HealthCare Ventures, Oxford Bi...
(Date:11/19/2008)...-- Posit Science Corporation,researcher, Dan Tink...ence,Annual Conference in Washington, DC this wee...Baby Boomers. The computerized brain plasticity-b...rcises that target auditory and,language systems....,improvements in cognition by improving speed and ...
(Date:11/19/2008)...ire/ -- Biotech scientists increasingly are applyi... better understand the effects of novel drug candi...tic Engineering & Biotechnology News ( GEN )....new compound,s mechanism of action and eventually ...rding to the November 15 issue of GEN . ( http://...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
Breaking Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Merrimack Pharmaceuticals Raises 2460 Million in Private Financing 5919 1Merrimack Pharmaceuticals Raises 2460 Million in Private Financing 5919 2Adding Light Eases Behavioral Problems of Dementia 21508 1Adding Light Eases Behavioral Problems of Dementia 21508 2Adding Light Eases Behavioral Problems of Dementia 21508 3New PA Economic Study 3A Bush Medicare Cuts Compound State Medicaid Crisis 21503 1New PA Economic Study 3A Bush Medicare Cuts Compound State Medicaid Crisis 21503 2Best in Class Engagement Programs 3A Employees See Link Between Quality 26 Performance 21498 1Best in Class Engagement Programs 3A Employees See Link Between Quality 26 Performance 21498 2
...K HEIGHTS, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - N...ay announced that,detailed results from the Compan...gn prostatic hyperplasia (BPH) will be presented a...nning in September,at the South Central American U... These independent podium presentations will be,gi...
... and REGENSBURG - June 21, 2007 - “In anapla...ually clearly superior,to temozolomide,” Pro...nia, U.S.A. commented on the international Phase,I...nder development,by Antisense Pharma. Prof. Wong d...scussion session on central nervous system tumors,...
Other Medicine Technology:Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S.,Urology Meetings 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4
(Date:11/21/2008)... do not cause genetic damage that can lead to dise... -- Two popular medications for treating attention...e genetic damage linked to an increased risk for d..., done by researchers at Duke University Medical C...ers a previous one that reported biomarkers associ...
(Date:11/21/2008).../ -- In a statewide survey, 33 physicians credenti...y at Presbyterian Hospital of Dallas were honored ... Super Doctors ." , , Each year, the publis... Media, Inc. to survey more than 38,000 medical pr...you needed medical care, which doctor would you ch...
(Date:11/21/2008)...wswire-FirstCall/ -- Symmetry Medical Inc. (NYSE: ...s to the global orthopedic device industry and oth...Moore, President and Chief Executive Officer, and ...ncial Officer, are scheduled to present at the 20t...he New York Palace Hotel on Wednesday, December 3,...
(Date:11/21/2008)...he University of Texas M. D. Anderson Cancer Cente...o eradicate breast cancer in Panama through the Pa... of the Americas today at an event with Laura Bush...Fernndez de Torrijos, the First Lady of Panama. ...he U.S. Department of State and Susan G. Komen for...
Breaking Medicine News(10 mins):Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...e cancer puts men at increased risk for diabetes a...servational study published in the// Sept. 20 Jour...er have high five-year survival rates, but they al...rtality than healthy men,” says study author Nancy...
...and Chile announced a tax on airline tickets to ra...ients who cannot afford them//. Representatives fr...Chirac of France and Luis Ignacio Lula da Silva of...ment at the UN. UN Secretary General Kofi Annan an...
...s revealed that Maori are almost twice as likely t...y to suffer// from mental disorder generally than ...Health Ministry has been the first to shed light o... disorders among different ethnic groups in this c...
...t increased levels of lipoprotein(a)are linked wit...healthy women according to Boston-based investigat...ralized screening of lipoprotein(a) in the populat...igh levels were associated with cardiovascular ris...
Other Medicine News:Health News:Prostate Cancer Treatment Increases Risk of Diabetes and Heart Disease 2Health News:High lipoprotein Levels in women Linked to Cardiovascular Risk 2
...dus laser lens design with Volk exclusive Double A...ion viewing and treatment of the optic nerve head ...heric optics provide improved performance over exi...mes standard with LaserWindow® for optimal las...
...Laser Lens affords the practitioner a direct uprig...izing a unique solid methyl methacrylate optic wit...erior, this special optical design eliminates fila...us lenses. Available in Volk's exclusive ANF+ (Adv...
...® is excellent for critically evaluating and t...from macular degeneration, retinal vascular occlus...ic retinopathy and other retinal conditions. It is...ns providing excellent magnification combined with...
...s designed for focal laser therapy and mid-to-far ...sign presents a realistic contour of the retinal c...f the entire posterior pole extending to the equat...c movement on the globe, therefore increasing its ...
Medicine Products: